Trial
NCT05181540
A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Angiocrine Bioscience
Collaborators
California Institute for Regenerative Medicine (CIRM)
Condition
Hodgkin Lymphoma
Intervention
AB-205
Why stopped
Interim analysis showed lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-04